CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Protide Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Protide Pharmaceuticals, Inc.
345 Memorial Drive, Suite A
Phone: (847) 726-3100p:847 726-3100 CRYSTAL LAKE, IL  60014  United States Ticker: PPMDPPMD

This company ceased filing statements with the SEC on 3/8/2004.

Business Summary
Protide Pharmaceuticals, Inc. is engaged in the discovery, development and advancement of technologies and processes in clinical cell therapy, regenerative medicine, transplantation and cell engineering. The Company offers a range of products, including serum replacements, cryopreservatives, cell processing and cell islet transplantation (CIT) islet cell solutions. The Company’s serum replacements product enables insight into cellular processes, as well as commercial production of recombinant therapeutic proteins, vaccines and other biological proteins. Its serum replacements product includes TCH, VaxMax, HemaPro, TM-235 and TCM. Its cryopreservatives products include Stemsol USP (DMSO), pZerve, Cellvation, MiCord 55% DMSO USP 5% Dextran USP and 2-8CELLsius + DMSO. Its cell processing products include 2-8CELLsius, Dextran 40 in 0.9% NaCl, Dulbecco’s Phosphate Buffered Saline (10X) PBS, Dulbecco’s Phosphate Buffered Saline (1X) PBS and Hank’s Balanced Salt Solution (1X) HBSS.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
2/28/20048/31/2003YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, President, Chief Executive Officer, Treasurer, Secretary Milo R.Polovina 50 1/1/1985 1/1/1985
Director John C.Stoner 73 7/1/2001 7/1/2001

Business Names
Business Name
PPMD
Protide Pharmaceuticals

General Information
Number of Employees: 5 (As of 10/31/2003)
Outstanding Shares: 4,029,134 (As of 3/31/2004)
Shareholders: 600
Stock Exchange: OTC
Federal Tax Id: 363384240
Fax Number: (847) 726-3110


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, August 28, 2023